4,501 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Purchased by Toroso Investments LLC

Share on StockTwits

Toroso Investments LLC acquired a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 4,501 shares of the biopharmaceutical company’s stock, valued at approximately $336,000.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in GILD. Norges Bank acquired a new stake in Gilead Sciences during the fourth quarter worth about $859,602,000. Capital Research Global Investors raised its stake in Gilead Sciences by 10.9% during the fourth quarter. Capital Research Global Investors now owns 85,132,885 shares of the biopharmaceutical company’s stock worth $5,531,935,000 after acquiring an additional 8,343,863 shares during the period. Valueworks LLC increased its stake in shares of Gilead Sciences by 7,777.5% in the fourth quarter. Valueworks LLC now owns 4,919,000 shares of the biopharmaceutical company’s stock valued at $6,146,000 after purchasing an additional 4,856,556 shares during the period. AQR Capital Management LLC increased its stake in shares of Gilead Sciences by 59.2% in the fourth quarter. AQR Capital Management LLC now owns 7,208,716 shares of the biopharmaceutical company’s stock valued at $464,529,000 after purchasing an additional 2,682,046 shares during the period. Finally, Renaissance Technologies LLC increased its stake in shares of Gilead Sciences by 15.1% in the fourth quarter. Renaissance Technologies LLC now owns 16,962,944 shares of the biopharmaceutical company’s stock valued at $1,102,252,000 after purchasing an additional 2,228,686 shares during the period. Hedge funds and other institutional investors own 77.34% of the company’s stock.

GILD traded down $0.51 during trading hours on Friday, hitting $72.99. 2,191,105 shares of the company’s stock were exchanged, compared to its average volume of 22,051,432. Gilead Sciences, Inc. has a 1-year low of $60.89 and a 1-year high of $85.97. The stock’s 50-day moving average is $77.81 and its two-hundred day moving average is $70.11. The stock has a market cap of $92.69 billion, a price-to-earnings ratio of 18.82, a PEG ratio of 3.16 and a beta of 0.72. The company has a quick ratio of 2.92, a current ratio of 3.04 and a debt-to-equity ratio of 1.00.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.68 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.57 by $0.11. Gilead Sciences had a net margin of 21.84% and a return on equity of 35.44%. The business had revenue of $5.55 billion during the quarter, compared to analysts’ expectations of $5.44 billion. During the same quarter in the prior year, the company posted $1.67 earnings per share. The firm’s revenue was up 5.1% on a year-over-year basis. On average, equities research analysts anticipate that Gilead Sciences, Inc. will post 6.34 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Monday, June 29th. Investors of record on Friday, June 12th will be issued a dividend of $0.68 per share. This represents a $2.72 annualized dividend and a yield of 3.73%. The ex-dividend date of this dividend is Thursday, June 11th. Gilead Sciences’s payout ratio is 44.30%.

In other Gilead Sciences news, EVP Brett A. Pletcher sold 10,441 shares of the company’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $70.88, for a total transaction of $740,058.08. Following the sale, the executive vice president now directly owns 25,085 shares of the company’s stock, valued at $1,778,024.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director John Francis Cogan sold 2,413 shares of the company’s stock in a transaction on Monday, March 16th. The stock was sold at an average price of $67.26, for a total transaction of $162,298.38. Following the sale, the director now directly owns 57,273 shares in the company, valued at $3,852,181.98. The disclosure for this sale can be found here. Insiders have sold 60,585 shares of company stock valued at $4,671,283 in the last 90 days. 0.13% of the stock is currently owned by corporate insiders.

Several brokerages have commented on GILD. Piper Sandler restated a “buy” rating and issued a $90.00 price target on shares of Gilead Sciences in a research note on Thursday. Jefferies Financial Group restated a “buy” rating and issued a $89.00 price target on shares of Gilead Sciences in a research note on Monday, April 13th. Morgan Stanley raised their price target on shares of Gilead Sciences from $75.00 to $77.00 and gave the company an “equal weight” rating in a research note on Friday, May 1st. Cantor Fitzgerald increased their price objective on shares of Gilead Sciences from $78.00 to $86.00 and gave the company an “overweight” rating in a report on Tuesday, April 7th. Finally, DZ Bank upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $80.00 price objective for the company in a report on Wednesday, March 18th. Seven equities research analysts have rated the stock with a sell rating, fifteen have given a hold rating and nine have assigned a buy rating to the company’s stock. Gilead Sciences has a consensus rating of “Hold” and a consensus target price of $78.15.

About Gilead Sciences

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Read More: Beige Book

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply